Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13D Filing: Lansdowne Partners and Summit Therapeutics PLC (ADR) (SMMT)

Summit Therapeutics PLC (ADR) (NASDAQ:SMMT): Alex Snow’s Lansdowne Partners filed an amended 13D.

You can check out Lansdowne Partners’ latest holdings and filings here.

Please follow Lansdowne Partners (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Lansdowne Partners or update its stock holdings.

Alex Snow
Alex Snow
Lansdowne Partners

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Lansdowne Partners (UK) L 0 19,060,500 0 19,060,500 19,060,500 27.11%
Lansdowne Developed Markets Master Fund Limited 0 19,060,500 0 19,060,500 19,060,500 27.11%
Alex Snow
Alex Snow
Lansdowne Partners

Page 1 of 8 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 13D/A
Amendment No. 2
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND
AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a)
Summit Therapeutics PLC
(Name of Issuer)
American Depositary Shares and Ordinary Shares, par value £0.01 per share
(Title of Class of Securities)
86627R102
(CUSIP Number)
Hugh Orange
c/o Lansdowne Partners (UK) LLP
15 Davies Street

London W1K 3AG

England

44-20-7290-5500
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
September 19, 2017
(Date of Event Which Requires Filing of this Statement)

If the filing
person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D/A, and
is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box o.

Note: Schedules
filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for
other parties to whom copies are to be sent.

* The remainder
of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of
securities and for any subsequent amendment containing information which would alter disclosures provided in the cover page.

The information
required on the remainder of this cover page shall not be deemed to be “filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the Notes).

Follow Summit Therapeutics Plc
Trade () Now!

Page 2 of 8 – SEC Filing

CUSIP No. 86627R102
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Lansdowne Partners (UK) LLP
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
(b) [_]
3. SEC USE ONLY
4. SOURCE OF FUNDS
AF
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e)
[_]
6. CITIZENSHIP OR PLACE OF ORGANIZATION
England
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
7. SOLE VOTING POWER
0
8. SHARED VOTING POWER
19,060,500[1]
9. SOLE DISPOSITIVE POWER
0
10. SHARED DISPOSITIVE POWER
19,060,500[1]
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
19,060,500[1]
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES
[_]
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
27.11%
14. TYPE OF REPORTING PERSON
IA

__________

[1]
The 19,060,500 Ordinary Shares beneficially owned consist of 11,077,170 Ordinary Shares and 1,596,666 American Depositary Shares,
which may be exchanged for Ordinary Shares at a 1:5 ratio.

Follow Summit Therapeutics Plc
Trade () Now!

Page 3 of 8 – SEC Filing

CUSIP No. 86627R102
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Lansdowne Developed Markets Master Fund Limited
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
(b) [_]
3. SEC USE ONLY
4. SOURCE OF FUNDS
WC
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e)
[_]
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
7. SOLE VOTING POWER
0
8. SHARED VOTING POWER
19,060,500[2]
9. SOLE DISPOSITIVE POWER
0
10. SHARED DISPOSITIVE POWER
]
19,060,500[2]
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
19,060,500[2]
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES
[_]
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
27.11%
14. TYPE OF REPORTING PERSON
CO

 __________

 

[2]
The 19,060,500 Ordinary Shares beneficially owned consist of 11,077,170 Ordinary Shares and 1,596,666 American Depositary Shares,
which may be exchanged for Ordinary Shares at a 1:5 ratio.

Follow Summit Therapeutics Plc
Trade () Now!

Page 4 of 8 – SEC Filing

CUSIP No. 86627R102 13D/A

Statement on Schedule 13D/A

ITEM 1.

SECURITY AND ISSUER.

This statement on Schedule
13D/A (the “Schedule 13D/A“) relates to the Ordinary Shares, par value £0.01 per share (the “Ordinary
Shares
“) and the American Depositary Shares, each representing five Ordinary Shares (the “ADSs” and
together with the Ordinary Shares, the “Shares”), of Summit Therapeutics PLC, a foreign private issuer incorporated
in England and Wales whose principal executive office is located at 136A Eastern Avenue, Milton Park, Abingdon, Oxfordshire OX14
4SB, United Kingdom (the “Issuer“).

ITEM 2.

IDENTITY AND BACKGROUND.

(a-c, f) This Schedule
13D/A is being filed on behalf of: (i) Lansdowne Partners (UK) LLP, an English limited liability partnership (“Lansdowne“)
and (ii) Lansdowne Developed Markets Master Fund Limited, a Cayman Islands exempted company (the “Fund” and together
with Lansdowne, the “Reporting Persons”). The Fund is a privately offered investment fund that holds the Shares
reported in this Schedule 13D/A. Lansdowne is the investment adviser to the Fund and as a result is the beneficial owner of the
Shares reported in this Schedule 13D/A.

The principal business address of Lansdowne
is 15 Davies Street, London W1K 3AG, England and the principal business address of the Fund is c/o BNP Paribas Fund Administration
Services, 2 Grand Canal Plaza, Grand Canal Street, Dublin 2, Ireland.

(d)       None
of the Reporting Persons, individually or collectively, has, during the last five years, been convicted in a criminal proceeding
(excluding traffic violations or similar misdemeanors).

(e)       None
of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body
of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future
violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with
respect to such laws.

ITEM 3.

SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

The funds for the purchase
of the Shares beneficially owned by the Reporting Persons came from the working capital of the Fund. The total cost for the Ordinary
Shares beneficially owned by the Reporting Persons is £18,676,103 and the total cost for the ADSs beneficially owned by the
Reporting Persons is $17,373,659. No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working
capital purposes (including certain leverage arrangements) in the ordinary course of business.

ITEM 4.

PURPOSE OF TRANSACTION.

The Reporting Persons hold
the securities described in Item 5 of this statement for investment purposes only.

The Reporting Persons have
no plan or proposal which relates to, or would result in, any of the actions enumerated in Item 4 of the instructions to Schedule
13D/A.

Follow Summit Therapeutics Plc
Trade () Now!

Page 5 of 8 – SEC Filing

ITEM 5.

INTEREST IN SECURITIES OF THE ISSUER.

(a – e) Regarding aggregate
beneficial ownership, see Row 11 of the cover page of each Reporting Person. Regarding percentage beneficial ownership, see Row
13 of the cover page of each Reporting Person. Regarding sole power to vote shares, see Row 7 of the cover page of each Reporting
Person. Regarding shared power to vote shares, see Row 8 of the cover page of each Reporting Person. Regarding sole power to dispose
of shares, see Row 9 of the cover page of each Reporting Person. Regarding shared power to dispose of shares, see Row 10 of the
cover page of each Reporting Person.

The transactions by the
Reporting Persons in the Shares during the past sixty days, which were open market transactions, are set forth in Exhibit B.

ITEM 6.

CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH
RESPECT TO SECURITIES OF THE ISSUER.

None

ITEM 7.

MATERIAL TO BE FILED AS EXHIBITS.

Exhibit A

Exhibit B

Joint Filing Agreement

Schedule of Transactions in Shares

Follow Summit Therapeutics Plc
Trade () Now!

Page 6 of 8 – SEC Filing

CUSIP No. 86627R102 13D/A

 

SIGNATURES

After reasonable
inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.

Date: September 20, 2017

Lansdowne Partners (UK) LLP /s/ Hugh Orange
Signature
Hugh Orange
Chief Compliance Officer
Lansdowne Developed Markets Master Fund Limited /s/ Hugh Orange
Signature
Hugh Orange
Chief Compliance Officer of its investment adviser

Follow Summit Therapeutics Plc
Trade () Now!

Page 7 of 8 – SEC Filing

Exhibit A

AGREEMENT

The undersigned agree that this Schedule 13D/A,
dated September 20, 2017, relating to the Ordinary Shares, par value £0.01 per share and the American Depositary Shares,
each representing five Ordinary Shares, of Summit Therapeutics PLC shall be filed on behalf of the undersigned.

Date: September 20, 2017

Lansdowne Partners (UK) LLP /s/ Hugh Orange
Signature
Hugh Orange
Chief Compliance Officer
Lansdowne Developed Markets Master Fund Limited /s/ Hugh Orange
Signature
Hugh Orange
Chief Compliance Officer of its investment adviser

Follow Summit Therapeutics Plc
Trade () Now!

Page 8 of 8 – SEC Filing

Exhibit B

Schedule
of Transactions in Shares

Date of Transaction Title of Class Number of
Shares Purchased
Number of
Shares Sold
Price
Per Share
9/19/17 American Depositary Shares[3] 666,666 $12.25

__________

[3]
The American Depositary Shares may be exchanged for Ordinary Shares, par value £0.01 per share, at a 1:5 ratio.

Follow Summit Therapeutics Plc
Trade () Now!